Op-ed views and opinions expressed are solely those of the author.

Robert F. Kennedy Jr. has reportedly secured the votes needed for confirmation as Secretary of Health and Human Services (HHS). For those who prioritize affordable healthcare and accountability for “Big Pharma,” this is a moment worth celebrating.

Kennedy has pledged to dismantle the immunity protections that shield drug manufacturers from responsibility for the efficacy and safety of their products. These protections currently enable pharmaceutical companies to evade accountability, whether their drugs heal or harm. This reform could mark a pivotal shift in the balance of power between patients and profit-driven pharmaceutical giants.

Moreover, RFK Jr. has vowed to slash drug prices—a commitment that could not come soon enough. Prescription drug costs are skyrocketing while pharmaceutical companies rake in record profits. Alarmingly, nearly 30% of Americans forgo prescribed medications because they simply cannot afford them. For Medicare patients alone, this affordability crisis could result in as many as one million deaths over the next year. Clearly, the current system is unsustainable, and Kennedy’s focus on reducing costs offers a glimmer of hope.

Kennedy also intends to put an end to Big Pharma’s practice of promoting expensive drugs, such as Ozempic, as quick fixes for issues that could be addressed through healthier lifestyles. Instead of pushing pharmaceuticals, he aims to encourage policies that prioritize whole foods, regular exercise, and preventive care—a refreshing approach that promotes long-term health over short-term profit.

Another critical focus for RFK Jr. is the regulation of pharmaceutical advertising. The United States is one of only two countries that permit drug companies to advertise directly to consumers on television. This practice creates a significant conflict of interest, particularly when pharmaceutical advertising dollars are a major revenue stream for news networks. Kennedy has promised to expose the extent to which Big Pharma influences media coverage, shedding light on the murky relationship between advertising dollars and public health narratives.

However, resistance remains in Congress, where some lawmakers continue to push agendas favorable to Big Pharma. One such effort involves targeting Pharmacy Benefit Managers (PBMs), entities that negotiate drug prices and save taxpayers billions annually. PBMs are a critical ally for the 275 million Americans enrolled in health plans that rely on their cost-saving strategies, particularly ones dealing with an expensive diagnosis like prostate cancer. Dismantling PBMs would be a disastrous move for consumers already struggling to afford essential medications.

In a recent near-miss, Republican lawmakers successfully blocked an attempt to undermine PBMs by attaching the issue to a critical year-end budget bill. With RFK Jr. at the helm of HHS, the campaign to erode PBMs’ effectiveness may finally lose momentum, bringing clarity and common sense to a debate too often clouded by corporate lobbying.

Kennedy’s leadership represents a stark departure from the Biden-Harris administration, which frequently aligned itself with pharmaceutical industry interests. From mandating COVID-19 vaccines for workers to prioritizing pharmaceutical agendas over individual autonomy, the previous administration often appeared more invested in satisfying Big Pharma than in addressing the health concerns of everyday Americans.

This alignment is hardly surprising when you consider that President Biden and Vice President Harris were among the top congressional recipients of Big Pharma donations. Despite Harris’s public claims of independence from pharmaceutical money, investigative reports have revealed substantial contributions from industry executives to her campaign—most of which remain unreturned. During her campaign, Harris, along with her ally Mark Cuban, even pledged to “crackdown” on PBMs, a move that would have undermined consumer interests.

Thankfully, the tide is turning. With RFK Jr. at the helm of HHS, the federal government has an opportunity to prioritize the health and freedom of the American people over the profits of pharmaceutical lobbyists and CEOs. It’s a vision that could truly “Make America Healthy Again,” and one that Americans across the political spectrum can rally behind.

• About
• Latest Posts

Julio Rivera

Julio Rivera is a business and political strategist, the Editorial Director for Reactionary Times and a political commentator and columnist. His writing, which is focused on cybersecurity and politics, has been published by websites including The Hill, Real Clear Politics, Townhall and American Thinker.

Latest posts by Julio Rivera (see all)

• Keeping your data away from online crooks this holiday shopping season - November 29, 2025
• Cybersecurity Awareness Month and the AWS wake-up call - November 1, 2025
• “Who’s Eating Your Pie?” — Erik Weir’s masterclass in applied financial stewardship - October 24, 2025

Comment

We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. Thank you for partnering with us to maintain fruitful conversation.